MOST OF THE PPIS ARE CURRENTLY AVAILABLE AS RACEMIC MIXTURES OF THE (R)-AND (S)-ENANTIOMERS IN EQUAL PROPORTIONS. ADMINISTRATION OF A RACEMATE IS THUS EQUIVALENT ADMINISTERING TWO DIFFERENT MOLECULAR IDENTITIES, WHICH MAY SIGNIFICANTLY DIFFER FROM EACH OTHER WITH RESPECT TO PHARMACO-DYNAMICS, PHARMACOKINETIOS AND THERAPEUTIC PROPERTIES. UNICHIRAL FORMULATIONS OF THE EXISTING PPIS HAVE ADVANTAGES IN TERMS OF METABOLISM AND BIOAVAILABILITY, THUS RESULTING IN BETTER DISEASE AND SYMPTOMS CONTROL. THUS, IT IS RATIONAL TO DEVELOP UNICHIRAL PPIS IN PLACE OF RACEMATES FOR BETTER/ IMPROVED THERAPEUTIC OUTCOMES.
DEXRABEPRAZOLE INHIBITS GASTRIC ACID SECRETION BY INHIBITING THE H*/K+-ATPASE PUMP IN GASTRIC PARIETAL CELLS. DEXRABEPRAZOLE DISSOCIATE MORE RAPIDLY AND COMPLETELY FROM H*/K*-ATPASE PUMP THAN OTHER PPIS WHICH SUGGESTS IT MAY BE A REVERSIBLE INHIBITOR OF THE PROTON PUMP. IN VITRO DATA DEMONSTRATES THAT DEXRABEPRAZOLE CAUSES DOSE-DEPENDENT INHIBITION OF ACID SECRETION WITH A RAPID ONSET OF ACTION AND SUPERIOR PHARMACOKINETIC PROFILE THAN OTHER PPIS.